BNTC CEO Jerel A. Banks receives 450K options at $13.53

Rhea-AI Filing Summary

Benitec Biopharma Inc. (BNTC) reported an equity award to its Chief Executive Officer and director, Jerel A. Banks, on a Form 4. On November 18, 2025, he received 450,000 stock options with an exercise price of $13.53 per share, giving him the right to buy Benitec common stock at that price.

The options have a long-term horizon, expiring on November 18, 2035. According to the filing, they will vest in 16 substantially equal quarterly installments, beginning on March 31, 2026. After this grant, Jerel A. Banks beneficially owned 450,000 stock options, held directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Banks Jerel A.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Options (right to buy)	450,000	$0.00	--

Holdings After Transaction: Options (right to buy) — 450,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Banks Jerel A.

(Last) (First) (Middle)

C/O BENITEC BIOPHARMA INC.

3940 TRUST WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Benitec Biopharma Inc. [ BNTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (right to buy)	$13.53	11/18/2025		A		450,000		(1)	11/18/2035	Common Stock	450,000	$0	450,000	D

Explanation of Responses:

1. The stock options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026.

	/s/ Jerel A. Banks	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity award did Benitec Biopharma (BNTC) grant to its CEO Jerel A. Banks?

Benitec Biopharma granted Jerel A. Banks 450,000 stock options, each giving the right to purchase one share of Benitec common stock.

What is the exercise price of Jerel A. Banks' Benitec Biopharma (BNTC) stock options?

The stock options granted to Jerel A. Banks have an exercise price of $13.53 per share.

When do Jerel A. Banks' Benitec Biopharma (BNTC) stock options vest?

The options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026.

When do Jerel A. Banks' stock options in Benitec Biopharma (BNTC) expire?

The options granted to Jerel A. Banks expire on November 18, 2035.

How many Benitec Biopharma (BNTC) derivative securities does Jerel A. Banks own after this transaction?

After the reported transaction, Jerel A. Banks beneficially owned 450,000 stock options, held directly.

What roles does Jerel A. Banks hold at Benitec Biopharma (BNTC)?

Jerel A. Banks is reported as both a Director and the Chief Executive Officer of Benitec Biopharma Inc.